<VariationArchive VariationID="659887" VariationName="NM_015474.4(SAMHD1):c.1476del (p.Lys492fs)" VariationType="Deletion" Accession="VCV000659887" Version="8" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-06-23" DateCreated="2019-08-14" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="648645" VariationID="659887">
      <GeneList>
        <Gene Symbol="SAMHD1" FullName="SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1" GeneID="25939" HGNC_ID="HGNC:15925" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>20q11.23</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="36889773" stop="36951708" display_start="36889773" display_stop="36951708" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="35520226" stop="35580245" display_start="35520226" display_stop="35580245" Strand="-" />
          </Location>
          <OMIM>606754</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_015474.4(SAMHD1):c.1476del (p.Lys492fs)</Name>
      <CanonicalSPDI>NC_000020.11:36904183:TTT:TT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>20q11.23</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="36904184" stop="36904184" display_start="36904184" display_stop="36904184" variantLength="1" positionVCF="36904183" referenceAlleleVCF="GT" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="35532587" stop="35532587" display_start="35532587" display_stop="35532587" variantLength="1" positionVCF="35532586" referenceAlleleVCF="GT" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>K492fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.10" sequenceAccession="NC_000020" sequenceVersion="10" change="g.35532589del" Assembly="GRCh37">
            <Expression>NC_000020.10:g.35532589del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.11" sequenceAccession="NC_000020" sequenceVersion="11" change="g.36904186del" Assembly="GRCh38">
            <Expression>NC_000020.11:g.36904186del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_017059.1" sequenceAccession="NG_017059" sequenceVersion="1" change="g.52660del">
            <Expression>NG_017059.1:g.52660del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363729.2" sequenceAccession="NM_001363729" sequenceVersion="2" change="c.1476del">
            <Expression>NM_001363729.2:c.1476del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350658.1" sequenceAccession="NP_001350658" sequenceVersion="1" change="p.Lys492fs">
            <Expression>NP_001350658.1:p.Lys492fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363733.2" sequenceAccession="NM_001363733" sequenceVersion="2" change="c.1476del">
            <Expression>NM_001363733.2:c.1476del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350662.1" sequenceAccession="NP_001350662" sequenceVersion="1" change="p.Lys492fs">
            <Expression>NP_001350662.1:p.Lys492fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_015474.4" sequenceAccession="NM_015474" sequenceVersion="4" change="c.1476del" MANESelect="true">
            <Expression>NM_015474.4:c.1476del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_056289.2" sequenceAccession="NP_056289" sequenceVersion="2" change="p.Lys492fs">
            <Expression>NP_056289.2:p.Lys492fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_281" sequenceAccession="LRG_281">
            <Expression>LRG_281:g.52660del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_015474.3" sequenceAccession="NM_015474" sequenceVersion="3" change="c.1476delA">
            <Expression>NM_015474.3:c.1476delA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="768409471" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_015474.4(SAMHD1):c.1476del (p.Lys492fs) AND Aicardi-Goutieres syndrome 5" Accession="RCV000816971" Version="7">
        <ClassifiedConditionList TraitSetID="1109">
          <ClassifiedCondition DB="MedGen" ID="C2749659">Aicardi-Goutieres syndrome 5</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-07-18" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_015474.4(SAMHD1):c.1476del (p.Lys492fs) AND Aicardi Goutieres syndrome" Accession="RCV001830789" Version="1">
        <ClassifiedConditionList TraitSetID="9630">
          <ClassifiedCondition DB="MedGen" ID="C0393591">Aicardi Goutieres syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2020-08-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_015474.4(SAMHD1):c.1476del (p.Lys492fs) AND multiple conditions" Accession="RCV002495159" Version="1">
        <ClassifiedConditionList TraitSetID="10411">
          <ClassifiedCondition DB="MedGen" ID="C2749659">Aicardi-Goutieres syndrome 5</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3280721">Chilblain lupus 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-11" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-07-18" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2019-08-14" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19525956</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22461318</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24183309</ID>
        </Citation>
        <DescriptionHistory Dated="2022-12-31">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="10411" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16768" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Chilblain lupus 2</ElementValue>
                <XRef ID="CHILBLAIN+LUPUS+2/7965" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013739" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CHBL2</ElementValue>
                <XRef Type="MIM" ID="614415" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Chilblain lupus is a rare cutaneous form of systemic lupus erythematosus (SLE; 152700) characterized by tender, bluish-red swellings and nodules on the hands, feet, ears, and nose, with histologic changes of lupus. The phenotype is induced by cold, such that patients frequently report a worsening of lesions in the winter months (summary by Ravenscroft et al., 2011).
For a general description and a discussion of genetic heterogeneity of chilblain lupus, see CHBL1 (610448).</Attribute>
                <XRef Type="MIM" ID="614415" DB="OMIM" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18494" />
                <XRef ID="18494" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="C3280721" DB="MedGen" />
              <XRef ID="MONDO:0013739" DB="MONDO" />
              <XRef Type="MIM" ID="614415" DB="OMIM" />
            </Trait>
            <Trait ID="6631" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Aicardi-Goutieres syndrome 5</ElementValue>
                <XRef ID="MONDO:0013059" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AGS5</ElementValue>
                <XRef Type="MIM" ID="612952" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Most characteristically, Aicardi-Goutières syndrome (AGS) manifests as an early-onset encephalopathy that usually, but not always, results in severe intellectual and physical disability. A subgroup of infants with AGS present at birth with abnormal neurologic findings, hepatosplenomegaly, elevated liver enzymes, and thrombocytopenia, a picture highly suggestive of congenital infection. Otherwise, most affected infants present at variable times after the first few weeks of life, frequently after a period of apparently normal development. Typically, they demonstrate the subacute onset of a severe encephalopathy characterized by extreme irritability, intermittent sterile pyrexias, loss of skills, and slowing of head growth. Over time, as many as 40% develop chilblain skin lesions on the fingers, toes, and ears. It is becoming apparent that atypical, sometimes milder, cases of AGS exist, and thus the true extent of the phenotype associated with pathogenic variants in the AGS-related genes is not yet known.</Attribute>
                <XRef ID="NBK1475" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10151" />
                <XRef ID="10151" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301648</ID>
                <ID Source="BookShelf">NBK1475</ID>
              </Citation>
              <XRef ID="51" DB="Orphanet" />
              <XRef ID="C2749659" DB="MedGen" />
              <XRef ID="MONDO:0013059" DB="MONDO" />
              <XRef Type="MIM" ID="612952" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1109" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6631" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Aicardi-Goutieres syndrome 5</ElementValue>
                <XRef ID="MONDO:0013059" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AGS5</ElementValue>
                <XRef Type="MIM" ID="612952" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Most characteristically, Aicardi-Goutières syndrome (AGS) manifests as an early-onset encephalopathy that usually, but not always, results in severe intellectual and physical disability. A subgroup of infants with AGS present at birth with abnormal neurologic findings, hepatosplenomegaly, elevated liver enzymes, and thrombocytopenia, a picture highly suggestive of congenital infection. Otherwise, most affected infants present at variable times after the first few weeks of life, frequently after a period of apparently normal development. Typically, they demonstrate the subacute onset of a severe encephalopathy characterized by extreme irritability, intermittent sterile pyrexias, loss of skills, and slowing of head growth. Over time, as many as 40% develop chilblain skin lesions on the fingers, toes, and ears. It is becoming apparent that atypical, sometimes milder, cases of AGS exist, and thus the true extent of the phenotype associated with pathogenic variants in the AGS-related genes is not yet known.</Attribute>
                <XRef ID="NBK1475" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10151" />
                <XRef ID="10151" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301648</ID>
                <ID Source="BookShelf">NBK1475</ID>
              </Citation>
              <XRef ID="51" DB="Orphanet" />
              <XRef ID="C2749659" DB="MedGen" />
              <XRef ID="MONDO:0013059" DB="MONDO" />
              <XRef Type="MIM" ID="612952" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9630" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="9456" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Aicardi Goutieres syndrome</ElementValue>
                <XRef ID="230312006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Encephalopathy, familial infantile, with calcification of basal ganglia and chronic cerebrospinal fluid lymphocytosis</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AGS1</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">AGS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Most characteristically, Aicardi-Goutières syndrome (AGS) manifests as an early-onset encephalopathy that usually, but not always, results in severe intellectual and physical disability. A subgroup of infants with AGS present at birth with abnormal neurologic findings, hepatosplenomegaly, elevated liver enzymes, and thrombocytopenia, a picture highly suggestive of congenital infection. Otherwise, most affected infants present at variable times after the first few weeks of life, frequently after a period of apparently normal development. Typically, they demonstrate the subacute onset of a severe encephalopathy characterized by extreme irritability, intermittent sterile pyrexias, loss of skills, and slowing of head growth. Over time, as many as 40% develop chilblain skin lesions on the fingers, toes, and ears. It is becoming apparent that atypical, sometimes milder, cases of AGS exist, and thus the true extent of the phenotype associated with pathogenic variants in the AGS-related genes is not yet known.</Attribute>
                <XRef ID="NBK1475" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="575" />
                <XRef ID="575" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301648</ID>
                <ID Source="BookShelf">NBK1475</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/X-ALD-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated lysophosphatidylcholines, X-Linked Adrenoleukodystrophy (X-ALD), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/X-ALD-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, X-ALD: Elevated lysophosphatidylcholines C24:0, C26:0, 2023</CitationText>
              </Citation>
              <XRef ID="51" DB="Orphanet" />
              <XRef ID="C0393591" DB="MedGen" />
              <XRef ID="MONDO:0018866" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS225750" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4081834" SubmissionDate="2022-02-09" DateLastUpdated="2022-02-13" DateCreated="2022-02-13">
        <ClinVarSubmissionID localKey="NM_015474.4:c.1476del|Aicardi-Goutieres syndrome" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002090974" DateUpdated="2022-02-13" DateCreated="2022-02-13" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-08-15">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_015474.4:c.1476del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Aicardi-Goutieres syndrome</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5432899" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_015474.4:c.1476del|OMIM:612952;614415" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002779992" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_015474.4:c.1476del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612952" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="614415" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1851748" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="4959986|MedGen:C2749659" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000957503" DateUpdated="2024-02-14" DateCreated="2019-08-14" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24183309</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19525956</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22461318</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 659887). This premature translational stop signal has been observed in individual(s) with Aicardi-Gouti√®ressyndrome (PMID: 24183309). This variant is present in population databases (rs768409471, gnomAD 0.002%). This sequence change creates a premature translational stop signal (p.Lys492Asnfs*2) in the SAMHD1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SAMHD1 are known to be pathogenic (PMID: 19525956, 22461318).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SAMHD1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000020.10:g.35532587del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2749659" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4081834" TraitType="Disease" MappingType="Name" MappingValue="Aicardi-Goutieres syndrome" MappingRef="Preferred">
        <MedGen CUI="C0393591" Name="Aicardi Goutieres syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1851748" TraitType="Disease" MappingType="XRef" MappingValue="C2749659" MappingRef="MedGen">
        <MedGen CUI="C2749659" Name="Aicardi-Goutieres syndrome 5" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5432899" TraitType="Disease" MappingType="XRef" MappingValue="612952" MappingRef="OMIM">
        <MedGen CUI="C2749659" Name="Aicardi-Goutieres syndrome 5" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5432899" TraitType="Disease" MappingType="XRef" MappingValue="614415" MappingRef="OMIM">
        <MedGen CUI="C3280721" Name="Chilblain lupus 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

